A Synthetic Peptide CTL Vaccine Targeting Nucleocapsid Confers Protection from SARS-CoV-2 Challenge in Rhesus Macaques.

Paul E HarrisTrevor BraselChristopher MasseyC V HerstScott BurkholzPeter LloydTikoes BlankenbergThomas M BeyRichard T CarbackThomas HodgeSerban CiotlosLu WangJason E ComerReid M Rubsamen

Published in: Vaccines (2021)

We demonstrate that a room temperature stable peptide vaccine based on known immunogenic HLA class I bound CTL epitopes from the nucleocapsid protein can provide protection against SARS-CoV-2 infection in nonhuman primates.

Keyphrases

respiratory syndrome coronavirus
room temperature
sars cov
coronavirus disease
ionic liquid
cancer therapy
amino acid
protein protein
binding protein
drug delivery
small molecule